Milnacipran inhibits oxaliplatin-induced mechanical allodynia through spinal action in mice.

Abstract

We investigated whether milnacipran, a serotonin-noradrenaline reuptake inhibitor, would have therapeutic effect on oxaliplatin-induced mechanical allodynia in mice. A single intraperitoneal injection of oxaliplatin (3 mg/kg) induced mechanical allodynia, which peaked on day 10 after injection and almost completely subsided by day 20. Ten days post-oxaliplatin injection, the intraperitoneal administration of milnacipran (3-30 mg/kg) significantly and dose-dependently inhibited the established mechanical allodynia. Intrathecal injections of milnacipran (2.1-21 µg/site) also significantly and dose-dependently inhibited mechanical allodynia, but intracisternal and intracereboventricular injections at the same doses did not. The present results suggest that milnacipran is effective against oxaliplatin-induced mechanical allodynia and that the antiallodynic effect is mainly mediated by actions on the spinal cord.

• Authors: Tsugunobu Andoh, Ryo Kitamura, Yasushi Kuraishi
• Journal: Biological & pharmaceutical bulletin (Biol Pharm Bull) Vol. 38 Issue 1 Pg. 151-4 ( 2015) ISSN: 1347-5215 [Electronic] Japan
• PMID: 25744472 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Cyclopropanes
• Organoplatinum Compounds
• Serotonin Uptake Inhibitors
• Oxaliplatin
• Milnacipran

Topics

• Animals
• Antineoplastic Agents
• Cyclopropanes (administration & dosage, therapeutic use)
• Drug Administration Routes
• Hyperalgesia (chemically induced, drug therapy)
• Male
• Mice, Inbred C57BL
• Milnacipran
• Organoplatinum Compounds
• Oxaliplatin
• Selective Serotonin Reuptake Inhibitors (administration & dosage, therapeutic use)
• Spinal Cord (drug effects)